Please login to the form below

Not currently logged in
Email:
Password:

non-Hodgkin's lymphoma

This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

bluebird bio to separate oncology and rare diseases units

bluebird bio to separate oncology and rare diseases units

Oncology Newco will be established as an independent organisation and will be led by bluebird bio’s current chief executive officer Nick Leschly. ... It will also retain research and development responsibilities for bluebird’s oncology pipeline of

Latest news

  • World Castleman Disease Day World Castleman Disease Day

    This isn't just the CDCN's fight or my fight. It's Our Fight. ... The disorder is just as serious and life-threatening as many rare blood cancers, including progressive non-Hodgkin’s lymphoma.

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and three solid tumours – colorectal, ovarian and bladder cancer. ... Magrolimab complements our existing work in haematology, adding a non-cell

  • Celgene’s Revlimid scores NICE approval in follicular lymphoma Celgene’s Revlimid scores NICE approval in follicular lymphoma

    New ‘chemotherapy-free’ treatment for patients with limited options. Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication ... lymphoma.

  • FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

    MCL is an aggressive type of non-Hodgkin’s lymphoma, and although it responds well to initial treatment, it eventually stops responding and the cancer cells continue to multiply. ... Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene

  • Givlaari, Rybelsus lead crowded CHMP recommendations Givlaari, Rybelsus lead crowded CHMP recommendations

    Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide). ... Biosimilar and generic medicines also had a wildly favourable turn

More from news
Approximately 15 fully matching, plus 126 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics